We have generated a mouse where the clotting factor IX (FIX) gene has been disrupted by homologous recombination. The FIX nullizygous (-/ -) mouse was devoid of factor IX antigen in plasma. Consistent with the bleeding disorder, the factor IX coagulant activities for wild-type (+/+), heterozygous (+/-), and homozygous (-/-) mice were 92%, 53%, and <5%, respectively, in activated partial thromboplastin time assays. Plasma factor IX activity in the deficient mice (-/-) was restored by introducing wild-type murine FIX gene via adenoviral vectors. Thus, these factor IX-deficient mice provide a useful animal model for gene therapy studies of hemophilia B.
Hemophilia B (Christmas disease or factor IX deficiency) is a bleeding disorder that is inherited as an X chromosome-linked recessive trait. The disease affects approximately 1 in 30,000 males and is distributed equally among ethnic groups (1, 2). The clinical presentation of the disease can be mild, moderate, or severe and is clinically indistinguishable from classic hemophilia A due to factor VIII deficiency (3, 4). Hemophilia B results from the absence of normal factor IX, a plasma serine protease that converts factor X to its active form, thereby propagating the well-orchestrated coagulation cascade (5). Affected individuals are treated with repeated injections of either human plasma factor IX concentrate or recombinant factor IX protein. Because this form of treatment is neither satisfactory nor long lasting, hemophilia B has become a very attractive target for gene therapy (6) .
Several investigators have used a variety of viral vectors to introduce factor IX genes in a variety of tissues in mice and hemophilic dogs. Retroviral vectors containing canine or human factor IX cDNA can efficiently transduce fibroblasts and produce biologically active factor IX protein; however, the expression is transient upon transplantation of transduced cells in the animals (7, 8) . The problem of long-term expression was overcome by the use of tissue-specific enhancers when in vitro-transduced mouse myoblasts were transplanted in vivo (9) . However, similar experiments failed when transduced dog myoblasts were transplanted in the hemophilic dogs (Y. Dai and I.M.V., unpublished data). Very low levels of sustained expression of factor IX could be detected in partially hepatectomized hemophilic dogs injected with canine factor IX recombinant retrovirus (10). Recombinant adenoviral vectors containing factor IX gene have been delivered directly in the muscle or liver of both nude and normal mice. The accumulated data show that although large amounts of biologically active factor IX protein is synthesized and secreted, the expression was only transient due to immunological problems (11, 12) . Recently, it has been shown that by using adenoassociated viral vectors, transduced factor IX gene is expressed at therapeutic levels in mouse liver and muscle for more than
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. ?1734 solely to indicate this fact. ? 1997 by The National Academy of Sciences 0027-8424/97/9411563-4$2.00/0 PNAS is available online at http://www.pnas.org. 6 months (13, 14). To investigate both long-term expression and the possible immunological problems caused by viral proteins, it was highly desirable to generate a factor IX "knock-out" mouse as an experimental model system. Herein we describe the generation and the characterization of a factor IX-deficient mouse. (Fig. 1A) . The targeting vector was linearized with NotI and introduced into the 129Sv embryonic stem (ES) cell line by electroporation, and stable transfectants were selected as described (16) . Individual ES clones were screened for homologous recombination by Southern blot analysis with an 800-bp fragment as a probe (Fig. 1A) . Positive ES clones were injected into C57BL/6 blastocysts as described (16) , and the resulting chimeric males were bred to C57BL/6 and 129Sv to establish an inbred line of mutant mice.
MATERIALS AND METHODS

Construction
Genotypes of mice were established by Southern blot hybridization using tail biopsy DNA as described above.
Northern Blot Analysis. Total RNA was prepared from mouse liver as described (17) . Twenty-microgram samples were fractionated by electrophoresis on denaturing agarose gel, transferred to nitrocellulose filters (18) , and hybridized to a 32P-labeled FIX probe. The FIX probe was prepared from a 2.7-kb BamHI fragment of a mouse FIX cDNA that covers the entire coding region of FIX gene.
Western Blot Analysis. Mouse plasma was subjected to barium citrate adsorption twice (19) . Four microliters of 1 M BaCl2 was added to 50 ,ul of mouse plasma, incubated at room temperature for 5 min, and centrifuged at 3,800 x g for 10 min. The precipitated proteins were dissolved in 25 ,ul of citratesaline buffer and precipitated again by BaCl2. The pellets were dissolved in 75 ,ul of citrate-saline buffer, and 10-,ul samples were electrophoresed through a SDS/12% polyacrylamide gel. The gel was blotted on a poly(vinylidene difluoride) membrane (Immobilon-P, Millipore), followed by sequential incubations with solutions containing rabbit anti-human factor IX antibody (A0300, Dako), and horseradish peroxidaseconjugated donkey anti-rabbit IgG antibody (Amersham). Knock-Out Mice Do Not Express Factor IX mRNA or Plasma Factor IX. FIX RNA was not detected in total liver RNA isolated from a homozygous (-/I-) mouse (Fig. 1C, lane  3) , by Northern blot hybridization using a FIX-specific probe, whereas appropriate amounts in the heterozygous (+/-; Fig.  1C, lane 2) and wild-type mice (Fig. 1C, lane 1) were easily detected when analyzed in parallel. No factor IX-specific protein could be identified by Western blot analysis of the plasma obtained from knock-out (-/-) mice with a polyclonal antibody against human factor IX (Fig. 1D, lane 4) . Fig. 2) . Interestingly, the female homozygous mice (-/--) give birth without complications. To quantify the amount and activity of factor IX protein, we determined coagulant activity of mouse plasma by using APTT clotting assays. Fig. 3 shows that the factor IX activity in knock-out mice (-/-) plasma was at least 20-fold lower (<5.4%) than that observed for the wild-type mice. The heterozygous mice (+/-) plasma had half as much activity (53%). The low level of apparent factor IX activity observed in deficient mice ( -I/-) was probably due to procoagulant activity generated in the process of blood sampling by ocular puncture. Thus, based on biological assays, the factor IX-deficient mice have little if any factor IX activity. Also, there are no significant differences between the factor IX-deficient female homozygotes and the male hemizygotes in the above tail-clip bleeding assays and APTT assays.
Correction of Factor IX Deficiency. To test whether the factor IX-deficient mice can be used as a model for gene therapy treatment, we generated recombinant adenovirus containing mouse FIX cDNA (rAd.mFIX) driven by the cy- tomegalovirus promoter/enhancer. Table 1 shows that intravenous injection of rAd.mFIXrestored the factor IX activity of the deficient mice by day 4 to 30-155% of the levels observed in wild-type mouse. However, the El-deleted replicationdefective adenoviral vectors are known to induce only transient expression of the transduced gene, it was therefore expected, as observed, that the biological activity of factor IX decreased to much lower levels by day 7 (11, 23). Nevertheless, restoration of factor IX activity in nullizygous (-/-) mice suggest that these factor IX-deficient mice can be used as model systems for gene therapy approaches.
DISCUSSION
Successful gene therapy approaches will require extensive validation of the technology in an experimental model system prior to undertaking clinical trials. For a variety of diseases, such as cancer and AIDS, it may not always be possible to have a good animal model system. But for genetic diseases, it will be very desirable to have a mouse model system to study the efficacy of the vector and immunological problems associated with the vector or the transgene and to monitor the vector safety. Toward this goal, we report the generation of mice where the gene encoding blood coagulation factor IX has been disrupted by homologous recombination. The evidence that the mice are factor IX-deficient is provided by (i) the absence of factor IX-specific RNA in the liver, (ii) the lack of factor IX protein by Western blot analysis in mouse plasma, (iii) little or no factor IX coagulant activity in the mouse plasma, and (iv) hematomas and bleeding episodes resulting from the slightest injury to the joints (Fig. 2) . Furthermore, when tail bleeds were performed, the wild-type mice stopped bleeding in 10-20 min, whereas the factor IX-deficient mice (-/-) continued to bleed past 240 min. After being injected with an adenoviral vector encoding mouse factor IX, FIX-deficient mice showed factor IX coagulant activity in plasma similar to that observed in normal mouse plasma. The ability of the recombinant adenoviruses encoding mouse factor IX to produce biologically active factor IX in plasma at levels of activity comparable to wild-type mouse suggests that this mouse can serve as an excellent model for testing gene therapy approaches using both viral and nonviral vectors. Although the engineered deletion in the FIX gene used for homologous recombination involved truncation of only 164 amino acids at the C terminus of the factor IX protein and the 3' untranslated region, there is no evidence of truncated factor IX mRNA or protein. Furthermore, it is yet not clear whether the factor IX-deficient mice will mount an immune response to factor IX proteins. Although factor IX-deficient dogs have served as good model systems (12), the factor IX-deficient mice will likely be a more tractable model for a variety of gene therapy approaches, novel drugs, or other modalities used to treat hemophilia B, because of the ease, comparative cost, and convenience associated with mouse systems.
